Evidence map›Paper›PMID 29566240›Full record

ArticleProtein engineering, design & selection : PEDS2018

Identification of high affinity HER2 binding antibodies using CHO Fab surface display.

Annalee W Nguyen, Kevin C Le, Jennifer A Maynard

Open access · bronzeAbstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Annalee W NguyenDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
Kevin C LeDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
Jennifer A MaynardDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
The University of Texas at Austin · US

Funding

Mammalian platform for identification of polyclonal antibody cancer therapiesF32GM111018 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI NGUYEN, ANNALEE W. · 2014 to 2016
$180k
NIGMS NIH HHS F32 GM111018
6 · The paper itself

Abstract

Discovery of monoclonal antibodies is most commonly performed using phage or yeast display but mammalian cells are used for production because of the complex antibody structure, including the multiple disulfide bonds and glycosylation, required for function. As this transition between host organisms is often accompanied by impaired binding, folding or expression, development pipelines include laborious plate-based screening or engineering strategies to adapt an antibody to mammalian expression. To circumvent these problems, we developed a plasmid-based Fab screening platform on Chinese hamster ovary (CHO) cells which allows for antibody selection in the production host and in the presence of the same post-translational modifications as the manufactured product. A hu4D5 variant with low affinity for the human epidermal growth factor receptor (HER2) growth factor receptor was mutagenized and this library of ~10(6) unique clones was screened to identify variants with up to 400-fold enhanced HER2 binding. After two rounds of fluorescence activated cell sorting (FACS), four unique clones exhibited improved antigen binding when expressed on the CHO surface or as purified human IgG. Three of the four clones contained free cysteines in third complementarity determining region of the antibody heavy chain, which did not impair expression or cause aggregation. The improved clones had similar yields and stabilities as hu4D5 and similar sub-nanomolar affinities as measured by equilibrium binding to target cells. The limited size of mammalian libraries restricts the utility of this approach for naïve antibody library screening, but it is a powerful approach for antibody affinity maturation or specificity enhancement and is readily generalizable to engineering other surface receptors, including T-cell receptors and chimeric antigen receptors.

Indexed as

Antibody AffinityAmino Acid SequenceAnimalsCHO CellsCricetulusErb-b2 Receptor Tyrosine KinasesHumansImmunoglobulin Fab FragmentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoglobulin Fab Fragments

Identifiers

PMID29566240
PMCPMC5892863
OpenAlexW2793406985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.